Audited Financial Results of the Company for half and financial year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 5.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hemant Surgical Industries reported strong FY2026 results with standalone revenue from operations growing 117% to Rs 23,098.71 lakhs from Rs 10,652.66 lakhs in FY2025. Profit after tax more than doubled to Rs 1,823.34 lakhs from Rs 813.21 lakhs, while basic EPS improved to Rs 15.42 from Rs 7.79. The company raised Rs 6,152.71 lakhs during the year through equity share and warrant issuances. EBITDA margin stands at approximately 12.3%, showing slight compression from prior year. Statutory auditors issued unmodified (clean) opinion for both standalone and consolidated results. Cash flow from operations was negative due to significant increases in trade receivables and inventories.
The company delivered exceptional revenue and profit growth in FY2026, driven by operational expansion. However, the sharp rise in trade receivables and negative operating cash flow suggest working capital stress that investors should monitor closely.